Green Tattoo Pre-Operative Renal Embolization for Robotic-Assisted and Laparoscopic Partial Nephrectomy: A Practical Proof of a New Technique.
embolization
green-tattoo technique
indocyanine
renal tumors
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
18 Nov 2022
18 Nov 2022
Historique:
received:
04
10
2022
revised:
03
11
2022
accepted:
13
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
27
11
2022
Statut:
epublish
Résumé
(1) Background: Our aim is to describe a new mixed indocyanine-non-adhesive liquid embolic agent (Onyx-18) pre-operative renal embolization technique for assisted-robotic and laparoscopic partial nephrectomy with near-infra-red fluorescence imaging. (2) Methods: Thirteen patients with biopsy-proven renal tumors underwent pre-operative mixed indocyanine-ethylene vinyl alcohol (EVOH) embolization (Green-embo) between June 2021 and August 2022. All pre-operative embolizations were performed with a super selective stop-flow technique using a balloon microcatheter to deliver an indocyanine-EVOH mixture into tertiary order arterial branch feeders and the intra-lesional vascular supply. Efficacy (evaluated as complete embolization, correct tumor mapping on infra-red fluorescence imaging and clamp-off surgery) and safety (evaluated as complication rate and functional outcomes) were primary goals. Clinical and pathological data were also collected. (3) Results: Two male and eleven female patients (mean age 72 years) received pre-operative Green-embo. The median tumor size was 29 mm (range 15-50 mm). Histopathology identified renal cell carcinoma (RCC) in 9 of the 13 (69%) patients, oncocytoma in 3 of the 13 (23%) patients and sarcomatoid RCC in 1 of the 13 (8%) patients. Lesions were equally distributed between polar, meso-renal, endo- and exophytic locations. Complete embolization was achieved in all the procedures. A correct green mapping was identified during all infra-red fluorescence imaging. All patients were discharged on the second day after the surgery. The median blood loss was 145 cc (10-300 cc). No significant differences were observed in serum creatinine levels before and after the embolization procedures. (4) Conclusions: The Green-tattoo technique based on a mixed indocyanine-non-adhesive liquid embolic agent (Onyx-18) is a safe and effective pre-operative embolization technique. The main advantages are the excellent lesion mapping for fluorescence imaging, reduction in surgical time, and definitive, complete and immediate tumor devascularization based on the deep Onyx-18 penetration, leading to a very low intra-operative blood loss.
Identifiants
pubmed: 36431293
pii: jcm11226816
doi: 10.3390/jcm11226816
pmc: PMC9693545
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int Urol Nephrol. 2013 Apr;45(2):381-5
pubmed: 23386247
Eur Urol. 2014 Feb;65(2):372-7
pubmed: 23850254
Int Urol Nephrol. 2012 Jun;44(3):753-9
pubmed: 22215306
Cardiovasc Intervent Radiol. 2016 Dec;39(12):1759-1764
pubmed: 27468838
Minerva Urol Nephrol. 2021 Aug;73(4):540-543
pubmed: 33200907
Int J Urol. 2016 Feb;23(2):122-31
pubmed: 26585191
Urology. 2014 Dec;84(6):1367-73
pubmed: 25440824
J Vasc Interv Radiol. 2022 Aug;33(8):934-941
pubmed: 35487346
Surg Oncol. 2017 Dec;26(4):377-381
pubmed: 29113655
Eur Urol Focus. 2018 Dec;4(6):960-968
pubmed: 28753888
Br J Urol. 1973 Oct;45(5):474-9
pubmed: 4748393
J Mater Chem B. 2020 Sep 23;8(36):8207-8218
pubmed: 32813005
Clin Imaging. 2021 Aug;76:205-212
pubmed: 33964598
Urology. 2012 Apr;79(4):958-64
pubmed: 22336035
Curr Urol Rep. 2015 Apr;16(4):20
pubmed: 25698588
Urology. 2012 Jul;80(1):110-6
pubmed: 22607949
Diagn Interv Radiol. 2020 Mar;26(2):140-142
pubmed: 32071021
Semin Intervent Radiol. 2014 Mar;31(1):70-81
pubmed: 24596442
Eur Urol Focus. 2020 May 15;6(3):505-512
pubmed: 30904340
Am J Clin Oncol. 2000 Feb;23(1):6-12
pubmed: 10683065
J Clin Oncol. 2017 Feb 20;35(6):668-680
pubmed: 28095147
BJU Int. 2017 Mar;119(3):456-463
pubmed: 27528265
Eur Urol. 2019 Jun;75(6):1008-1014
pubmed: 30262342